The split in outlook underscores Lilly’s strong position in the obesity market, underpinned by more effective drugs and its direct-to-consumer sales strategy.
The split in outlook underscores Lilly’s strong position in the obesity market, underpinned by more effective drugs and its direct-to-consumer sales strategy.